Torrent Pharmaceuticals Limited (TORNTPHARM) Revenue 2023–TTM

Name: Torrent Pharmaceuticals Limited (TORNTPHARM) revenue history 2023-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-10-27

Torrent Pharmaceuticals Limited annual revenue for fiscal TTM was ₹171.1 billion, an increase of 24.4% from ₹137.5 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

TORNTPHARM Annual Revenue

Revenue (annual)	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹171.1B	₹137.5B	₹113.2B	₹105.6B	₹94.6B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TORNTPHARM Quarterly Revenue

Revenue (quarterly)	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30
Total Revenue	₹49.0B	₹48.4B	₹41.3B	₹32.5B	₹32.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

4502 Revenue — Takeda Pharmaceutical Company Limited
SUNPHARMA Revenue — Sun Pharmaceutical Industries Limited
DIVISLAB Revenue — Divi's Laboratories Limited
4507 Revenue — Shionogi & Co., Ltd.
4523 Revenue — Eisai Co., Ltd.
4151 Revenue — Kyowa Kirin Co., Ltd.

More TORNTPHARM metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All TORNTPHARM financial statements → Interactive TORNTPHARM charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.